🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareThe "Ozempic face" phenomenon — adipose redistribution or volume loss? Page 3

The "Ozempic face" phenomenon — adipose redistribution or volume loss?

Dr.Martinez Wed, May 6, 2026 at 9:00 AM 14 replies 747 viewsPage 3 of 3
HPLC_Greg
Senior Member
1,890
8,901
Feb 2024
Research Triangle, NC
May 13, 2026 at 7:03 AM#11
LindaRN_retired said:
There is a difference between no evidence and evidence of no effect, and this subject is one where the two get swapped freely in both directions.

Agreed, though "tolerable" needs defining. A dose you tolerate by eating almost nothing is not tolerated, it is being paid for somewhere else — usually in lean mass, sometimes in adherence three months later.

Last edited: May 13, 2026 at 1:03 PM
8 6SallyK_inj, CryptoCarl, MariaRD and 5 others
Reply Quote Save Share Report
B12Beth
Member
289
890
Oct 2024
Maryland
May 14, 2026 at 2:20 PM#12
NurseKim_ATL said:
Steady state is the thing most people miss.

This answered a question I did not know how to ask. Sending this to two other people who asked me the same thing last week.

9 7carl_compliance, DanielChem_CHI, marco_milano and 6 others
Reply Quote Save Share Report
JessicaH_TX
Senior Member
4,123
13,456
Dec 2023
Houston, TX
May 15, 2026 at 9:36 PM#13
LindaRN_retired said:
There is a difference between no evidence and evidence of no effect, and this subject is one where the two get swapped freely in both directions.

I will push back on the "any working dose is fine" framing. The maintenance evidence sits overwhelmingly at the top studied dose, and the extension data shows regain tracking dose reduction rather than tracking stopping. Holding low is reasonable; pretending it is evidentially equivalent is not.

Last edited: May 16, 2026 at 1:36 AM
10 8kim_atl_prep, sarah_TO, wendy_avl and 7 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
jason_paloalto
Member
212
890
Nov 2024
Palo Alto, CA
May 17, 2026 at 4:52 AM#14

The figures, for anyone assembling their own picture. Practical: whatever you change, write down the date and the reason. In three months the reason is what you will have forgotten, and the reason is what makes the record worth having.

11 9andrew_nyc, Dr.EndoEP, GraceAZ_72 and 8 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
May 18, 2026 at 12:07 PM#15

Moderator note: reminder that nothing in this thread is medical advice, and that clinical claims need a source.

12 10PurityPaulOR, MaxMetOK, MounjBrad and 9 others
Reply Quote Save Share Report

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register